Literature DB >> 30921546

Public preferences for One Health approaches to emerging infectious diseases: A discrete choice experiment.

Jane Johnson1, Kirsten Howard2, Andrew Wilson3, Michael Ward4, Gwendolyn L Gilbert5, Chris Degeling6.   

Abstract

There is increasing scientific consensus that a One Health approach (acknowledging links between human, animal and environmental health) is the most effective way of responding to emerging infectious disease (EID) threats. However, reviews of past EID events show that successful implementation of control strategies hinge on alignment with public values. Given the limited evidence about public values in this area, we sought to understand public preferences for attributes associated with One Health strategies for EID prevention and control, using a discrete choice experiment (DCE). The DCE was conducted in 2016 using an online panel of Australian respondents aged over 18. Participants were presented with 18 pairs of scenarios describing One Health strategies and outcomes, and asked to select their preferred one. Scenarios were described by nine attributes with varying levels: personal autonomy, economic development, environmental health, community cohesion, free trade and travel, zoonotic risk, mortality, animal welfare and food security. Respondents were broadly representative of the Australian population (n = 1999, mean age 45.3 years (range 18-89); 50.7% male). The public preferred scenarios in which individual freedoms are not restricted for the greater good; unemployment is low; the environment is healthy; there is good community cohesion; travel, imports and exports are tightly controlled; there is lower mortality and incidence of disease; and where animal welfare and food security are protected. Although lower morbidity and mortality were preferable, respondents were willing to accept extra cases of severe disease and deaths to avoid reductions in some attributes. However, a mixed logit model indicated significant heterogeneity. A latent class analysis suggested wide variability across respondent classes in the valuation of attributes, and the trade-offs respondents were willing to accept. Therefore, a single approach to managing EID using One Health is unlikely to be acceptable to all community members.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Australia; Discrete choice experiment; Emerging infectious diseases; One health; Public policy

Mesh:

Year:  2019        PMID: 30921546     DOI: 10.1016/j.socscimed.2019.03.013

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  5 in total

1.  Preferences for Primary Healthcare Services Among Older Adults with Chronic Disease: A Discrete Choice Experiment.

Authors:  Yingying Peng; Mingzhu Jiang; Xiao Shen; Xianglin Li; Erping Jia; Juyang Xiong
Journal:  Patient Prefer Adherence       Date:  2020-09-17       Impact factor: 2.711

2.  Understanding public preferences and trade-offs for government responses during a pandemic: a protocol for a discrete choice experiment in the UK.

Authors:  Mesfin G Genie; Luis Enrique Loría-Rebolledo; Shantini Paranjothy; Daniel Powell; Mandy Ryan; Ruben Andreas Sakowsky; Verity Watson
Journal:  BMJ Open       Date:  2020-11-20       Impact factor: 2.692

3.  Public acceptability of non-pharmaceutical interventions to control a pandemic in the UK: a discrete choice experiment.

Authors:  Luis Enrique Loría-Rebolledo; Mandy Ryan; Verity Watson; Mesfin G Genie; Ruben Andreas Sakowsky; Daniel Powell; Shantini Paranjothy
Journal:  BMJ Open       Date:  2022-03-08       Impact factor: 2.692

4.  Public Policies and One Health in Brazil: The Challenge of the Disarticulation.

Authors:  Isis de Freitas Espeschit; Clara Marques Santana; Maria Aparecida Scatamburlo Moreira
Journal:  Front Public Health       Date:  2021-06-04

Review 5.  Rabies in Our Neighbourhood: Preparedness for an Emerging Infectious Disease.

Authors:  Michael P Ward; Victoria J Brookes
Journal:  Pathogens       Date:  2021-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.